Effects of metformin on polycystic ovary syndrome
Abstract
Polycystic ovary syndrome(PCOS) is characterized by reproductive and metabolic abnormalities.Hyperinsulinemia and insulin resistance which result in hyperandrogenemia have been documented as a central role in the pathogenesis of PCOS.Treatment with insulin sensitizer,metformin,has been shown to be followed by regularization of menstrual cycle,improved response to ovulation induction and reduction of hyperandrogenism.It possibly prevents early trimester pregnancy loss and decreases the risk of developing type II diabetes and cardiovascular disease.This article aims to review the current evidence on the use of metformin in women with PCOS.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.